Search This Blog

Wednesday, May 27, 2026

HCW Biologics regains full ex vivo rights to HCW9206 and HCW9201

 

HCW Biologics regains full ex vivo rights to HCW9206 and HCW9201 from Wugen at no cost

  • Company retains prior upfront license fee and 2.2 million Wugen shares despite exercising option.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)